CHMP updates Cerezyme recommendations

EMEA's CHMP issued updated temporary treatment recommendations for the use of Cerezyme imiglucerase from Genzyme Corp. (NASDAQ:GENZ) during the ongoing shortage of the Gaucher's disease drug. This is the third set of Cerezyme recommendations CHMP has issued since Genzyme temporarily stopped production at its Allston, Mass., manufacturing facility in June due to a virus found in a bioreactor. ...